Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest & Investment Income: 2011-2025

Historic Interest & Investment Income for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $376,000.

  • Adma Biologics' Interest & Investment Income fell 43.54% to $376,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 6.11%. This contributed to the annual value of $2.1 million for FY2024, which is 29.68% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Interest & Investment Income is $376,000, which was down 6.00% from $400,000 recorded in Q2 2025.
  • Adma Biologics' Interest & Investment Income's 5-year high stood at $666,000 during Q3 2024, with a 5-year trough of $2,269 in Q2 2022.
  • For the 3-year period, Adma Biologics' Interest & Investment Income averaged around $463,273, with its median value being $423,000 (2023).
  • In the last 5 years, Adma Biologics' Interest & Investment Income plummeted by 91.11% in 2021 and then soared by 25,116.32% in 2023.
  • Adma Biologics' Interest & Investment Income (Quarterly) stood at $2,759 in 2021, then fell by 12.03% to $2,427 in 2022, then skyrocketed by 25,116.32% to $612,000 in 2023, then decreased by 2.29% to $598,000 in 2024, then plummeted by 43.54% to $376,000 in 2025.
  • Its last three reported values are $376,000 in Q3 2025, $400,000 for Q2 2025, and $608,000 during Q1 2025.